Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT

Pfizer Inc. (NYSE:PFE) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider of Goldman Sachs maintained a Hold rating on Pfizer Inc. (NYSE:PFE) on June 11, retaining the price target of $27.00. The rating was based on the company’s strategic direction and current business environment.

The analyst stated that management is optimistic about the upcoming earnings and the benefits of recent strategic deals, especially in the PD1-VEGF bispecifics and ADC portfolio combinations. Despite these positive factors, uncertainties in the broader policy environment persist. This includes drug pricing, with ongoing discussions with the administration.

Haider further opined that although Pfizer Inc. (NYSE:PFE) has a clear focus on internal medicine and plans to engage in smaller M&A deals, the ongoing evolving pricing dynamics in the obesity and cardiometabolic sectors pose difficulties. The company’s focus on upholding its dividend as a capital allocation policy is another factor that justifies the Hold rating.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets and sells biopharmaceutical products worldwide. The company takes the fourth spot on our list of the best drug stocks to invest in according to hedge funds. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.